ERBB2 and neoplasm: Furthermore, in a non-pathogen-related cancer vaccination study using D2F2/E2 mouse tumours, the gene gun provided better tumour protection at day 25, after two immunisations with a HER2/neu-coding plasmid at day 0 and day 15.